Effect of dimethyl fumarate in patients with plaque psoriasis meeting the upgrade criteria required for moderate‐to‐severe disease classification

• Váldodahkkit: Sascha Gerdes (Dahkki), Philipp Al Ghazal (Dahkki), Sebastian Diemert (Dahkki), Christian Termeer (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2024-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Background Oral dimethyl fumarate (DMF) is indicated in patients with plaque psoriasis requiring systemic treatment, including those meeting the upgrade criteria for moderate‐to‐severe disease classification. Objectives To evaluate quality of life (QoL), effectiveness, and tolerability of D...